MANGALAM vs PANACEABIO: Stock Comparison

Mangalam Drugs And Organics Limited vs Panacea Biotec Limited

Live data: 22 July 2026, 2:57 PM IST • Source: NSE and company filings

Panacea Biotec Limited is the larger company by market capitalisation. Panacea Biotec Limited shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Mangalam Drugs And Organics Limited and Panacea Biotec Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, MANGALAM is more favourable on 1 of 11 scored metrics and PANACEABIO on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
PANACEABIO is the larger company
₹2,836 Cr vs ₹43 Cr
EPS
PANACEABIO has higher earnings per share
₹-0.94 vs ₹-28.05
Revenue Growth (TTM YoY)
PANACEABIO has faster revenue growth
1% vs -7.5%
EPS Growth (TTM YoY)
MANGALAM has faster EPS growth
0% vs -12.2%
Qtr Sales Growth
PANACEABIO has stronger quarterly sales growth
25.8% vs -7.54%
Qtr Profit Growth
PANACEABIO has stronger quarterly profit growth
93% vs -22,467%
ROE
PANACEABIO has a higher ROE
-2.36% vs -35.2%
ROCE
PANACEABIO has a higher ROCE
-2.44% vs -14.3%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricMANGALAMPANACEABIO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricMANGALAMPANACEABIO
Live Price₹27.08₹464.65
Day Change-0.66%-5.94%
Volume25,3566.33 L
52-Week High₹95₹647
52-Week Low₹22.8₹292.4
Distance from 52W High-71.49%-28.18%

Valuation

MetricMANGALAMPANACEABIO
Market Cap₹43 Cr₹2,836 Cr
P/E Ratio-561.99x
P/B Ratio3.63x
EPS₹-28.05₹-0.94
Book Value₹65.12₹128.44
Dividend Yield0%0%

Growth

MetricMANGALAMPANACEABIO
Revenue Growth (TTM YoY)-7.5%1%
EPS Growth (TTM YoY)0%-12.2%
Qtr Sales Growth-7.54%25.8%
Qtr Profit Growth-22,467%93%

Profitability & Leverage

MetricMANGALAMPANACEABIO
ROE-35.2%-2.36%
ROCE-14.3%-2.44%
Net Margin-19.13%-0.84%
Operating Margin-6.42%-0.73%
Debt to Equity1.02x0.03x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricMANGALAMPANACEABIO
Promoter Holding35.65%72.48%
FII Holding0.11% 0.21 pp1.6% 0.24 pp
DII Holding0%1.97% 0.12 pp
Public Holding64.24% 0.22 pp23.96% 0.34 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Mangalam Drugs And Organics Limited and Panacea Biotec Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.